Arenavirus-based vaccine

About HOOKIPA Pharma

HOOKIPA Pharma's mission is to harness the power of the immune system to combat serious infectious diseases and cancers. Its core technology utilizes engineered replicating arenavirus vectors, both lymphocytic choriomeningitis virus (LCMV) and Pichinde virus (PICV), designed to elicit robust and durable antigen-specific CD8+ T cell responses. The company has advanced multiple candidates into clinical trials through internal development and strategic partnerships, including with Gilead Sciences and Roche, positioning itself at the forefront of next-generation immunotherapy platforms.

About HOOKIPA Pharma

HOOKIPA Pharma's mission is to harness the power of the immune system to combat serious infectious diseases and cancers. Its core technology utilizes engineered replicating arenavirus vectors, both lymphocytic choriomeningitis virus (LCMV) and Pichinde virus (PICV), designed to elicit robust and durable antigen-specific CD8+ T cell responses. The company has advanced multiple candidates into clinical trials through internal development and strategic partnerships, including with Gilead Sciences and Roche, positioning itself at the forefront of next-generation immunotherapy platforms.

Therapeutic Areas